Related Experiment Videos
Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer
1Department of Urology, Nagasaki University School of Medicine, Sakamoto, Japan. ttsuru-ngs@umin.u-tokyo.ac.jp
Background:
Previous studies have shown that beta-microseminoprotein (beta-MSP) may be used as a diagnostic marker for prostate cancer. However, the level of expression of beta-MSP in prostate cancer detected by immunohistochemistry (IHC) has varied from one study to another.
Methods:
We analyzed the expression of both beta-MSP mRNA and its protein in a large sample of prostate tumors from 104 patients with untreated prostate cancer, using both nonradioactive in situ hybridization (ISH) and IHC.
Results:
Our results showed that 72 and 96 of 104 specimens were negative for beta-MSP mRNA (69.2%) and beta-MSP (92.3%), respectively. Furthermore, a reduced expression of both beta-MSP mRNA and its protein was detected in all malignant epithelial tissues compared with benign epithelia. Not all malignant tissue samples negative for beta-MSP mRNA were negative for beta-MSP (6.7%), and vice versa (29.8%). Other tissue samples were either negative for both (62.5%) or positive for both (1.0%).
Conclusions:
Our results showed a lower level of expression of beta-MSP in prostate cancer tissue, compared with benign prostate tissue. This phenomenon may be mainly due to the presence of reduced levels of beta-MSP mRNA.
Insights
Beta-microseminoprotein (beta-MSP) expression is lower in prostate cancer tissue than in benign tissue. Reduced beta-microseminoprotein mRNA levels likely cause this difference, impacting its use as a prostate cancer diagnostic marker.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Beta-microseminoprotein (beta-MSP) has been investigated as a potential diagnostic marker for prostate cancer.
- Previous immunohistochemistry (IHC) studies reported variable beta-MSP expression levels in prostate cancer.
Purpose of the Study:
- To investigate the expression of beta-microseminoprotein (beta-MSP) mRNA and protein in prostate cancer.
- To clarify the discrepancy in beta-MSP expression levels observed in prior studies.
Main Methods:
- Analyzed beta-MSP mRNA and protein expression in 104 untreated prostate cancer tumors.
- Utilized nonradioactive in situ hybridization (ISH) and immunohistochemistry (IHC) for analysis.
Main Results:
- 72% of specimens were negative for beta-MSP mRNA and 96% were negative for beta-MSP protein.
- Malignant tissues showed reduced beta-MSP mRNA and protein expression compared to benign epithelia.
- Discrepancies in beta-MSP mRNA and protein negativity were observed in malignant samples.
Conclusions:
- Prostate cancer tissue exhibits lower beta-microseminoprotein (beta-MSP) expression than benign prostate tissue.
- Reduced beta-MSP mRNA levels are the primary factor contributing to decreased beta-MSP expression in prostate cancer.